
When FIRSTPICK backed Emilė Radytė in 2021, her company Samphire Neuroscience was still building its first product and the risk, by the fund’s own assessment, was high. There was no revenue, no clear route to market, and a proposition, a n
No discussion yet. Be the first to share your thoughts!